Article

Hackensack Meridian Health John Theurer Center to Receive $90,000 from E's Battle Buddies, Kids Fighting Cancer

Author(s):

Funds will help support rare cancer research and families in need.

Hackensack Meridian Health John Theurer Cancer Center at Hackensack University Medical Center will be accepting a generous donation of $90,000 from E’s Battle Buddies — Kids Fighting Cancer.

E’s Battle Buddies, a charity affiliated with Hackensack University Medical Center, raises money for rare cancer research and those going through the disease. Ethan Sandlofer, 10, of Saddle River, NJ, created the charity under the guidance of his father Jason Sandlofer, and with help from family and friends. Sandlofer started the nonprofit to honor his late mother, Gaby Sandlofer.

In May, E's Battle Buddies hosted a fundraiser at Lifetime Athletic Bergen County in Montvale. The kids-only event provided high energy, interactive activities, such as indoor cycling and obstacle runs, while raising money and awareness for lifesaving rare cancer research, and teaching kids the importance of giving back.

When: Thursday, November 9

4:00 p.m.

Where: Hackensack University Medical Center

John Theurer Cancer Center

92 Second Street

Hackensack, NJ 07601

For security purposes, planning and parking instructions, members of the media interested in covering this event are asked contact Katherine Emmanouilidis, John Theurer Cancer Center Communications and Public Relations Department, at 551-996-3764 (office) 201-956-7191 (cell) or Katherine.Emmanouilidis@hackensackmeridian.org.

Related Videos
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
David Samuel Dicapua Siegel, MD
Noa Biran, MD
Noa Biran, MD